Regulus Therapeutics (RGLS) Upgraded at Zacks Investment Research
Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The brokerage currently has a $1.25 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 5.93% from the stock’s current price.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
A number of other equities analysts also recently commented on RGLS. Wedbush restated an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research note on Monday, December 11th. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $2.55.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP boosted its stake in shares of Regulus Therapeutics by 44.8% during the third quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 63,100 shares in the last quarter. South Dakota Investment Council boosted its stake in shares of Regulus Therapeutics by 37.1% during the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock valued at $2,275,000 after purchasing an additional 492,969 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $750,000. NEA Management Company LLC bought a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $13,737,000. Finally, Victory Capital Management Inc. bought a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $347,000. Hedge funds and other institutional investors own 59.39% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Regulus Therapeutics (RGLS) Upgraded at Zacks Investment Research” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/04/regulus-therapeutics-rgls-upgraded-at-zacks-investment-research.html.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.